BRCA2 p.Tyr2726Cys
c.8177A>G · rs80359064 · VCV52520
Computational evidence
| Protein change | ||
| AlphaMissense | 0.8863 | likely pathogenic ✓ concordant with ClinVar · top 2% in BRCA2 |
|---|---|---|
| REVEL | 0.928 | moderately pathogenic-leaning |
| ⇒ AlphaMissense and REVEL both call this damaging. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 11 | GERP 2.3, phastCons 1 |
| Regional constraint | o/e 1.03 | unconstrained · MANE · 47 kb · p 0.059 · regional, not allelic |
| Overall | ||
| CADD | 26.1 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
gnomAD v4.1 · exomes + genomes| Ancestry group | Frequency | 1 in |
|---|---|---|
| Finnishnot grpmax-eligible | 0.00312% | 32,022 |
| South Asiangrpmax | 0.0011% | 91,092 |
| European (non-Finnish) | 0.000169% | 590,016 |
Finnish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- BRCA2
- Protein
- p.Tyr2726Cys
- Coding
- c.8177A>G
- MANE Select
- NM_000059
- dbSNP
- rs80359064
- Type
- single nucleotide variant
- Location
- chr13:32363379 (GRCh38)
- Gene constraint
- LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
- Residue 2726
- the 'interaction with sem1' region
Disease context
BRCA2-related cancer predisposition — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: hereditary breast ovarian cancer syndromebreast-ovarian cancer, familial, susceptibility to, 2hereditary neoplastic syndromehereditary breast carcinoma
Similar variants
- BRCA2 p.Tyr2726Ter Pathogenic ★★★ same residue
- BRCA2 p.Tyr2726= Benign/Likely benign ★★ same residue
- BRCA2 p.Tyr2726Asn Likely pathogenic ★ same residue
- BRCA2 p.Tyr2726Phe Uncertain significance ★ ⚠ same residue
- BRCA2 c.316+1G>T Pathogenic ★★★ same condition
- BRCA2 c.316+2T>C Pathogenic ★★★ same condition
- BRCA2 c.316+5G>A Pathogenic ★★★ same condition
- BRCA2 c.316+5G>C Pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-tyr2726cys (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown